Dr. Barata stresses significance of tumor sequencing in urothelial carcinoma

“The real-world data suggest that the use of tumor sequencing is definitely suboptimal,” says Pedro C. Barata, MD, MSc.

Pedro C. Barata, MD, MSc, an associate professor of Medicine in Hematology and Medical Oncology at the Tulane University School of Medicine, discusses the importance of tumor sequencing to the implementation of precision medicine for patients with urothelial carcinoma.